CBS.MarketWatch.com

The makers of Prozac and osteoporosis drug Evista (LLY)
LLY, +0.00%
earned $595 million, or 53 cents per share in the third quarter, beating First Call consensus estimates of 51 cents. The number excludes a one-time charge of $127.5 million, or 7 cents per share, on payments made during the quarter for a research collaboration with ICOS Corp. on male and female sexual dysfunction.

Including the charges, Eli Lilly earned $518.2 million or 46 cents per share, compared to $456.9 million, or 40 cents a year-ago.

Shares rose 2 5/8 to 78 in afternoon trading, off from a 52-week high of 81 5/8 hit on Sept. 23.

Worldwide sales rose to $2.57 billion from $2.16 billion a year-ago. Prozac and the anti-schizophrenia drug Zyprexa were the company's top-selling drugs.

Prozac sales jumped 12 percent to $793 million, while Zyprexa sales doubled over the year-ago period to $396.2 million. Sales of Evista, just introduced in the first quarter, were $33.2 million.

Chief Executive Officer Sidney Taurel said in a statement that Lilly experienced an "eventful" quarter, with strong sales and successful new products.

Intraday Data provided by SIX Financial Information and subject to terms of use. Historical and current end-of-day data provided by SIX Financial Information. All quotes are in local exchange time. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements.